期刊文献+

经尿道电切术联合吉西他滨灌注治疗膀胱癌的临床效果观察

Clinical Observation of Transurethral Resection Combined with Gemcitabine in Treatment of Bladder Cancer
下载PDF
导出
摘要 目的 观察经尿道电切术联合吉西他滨灌注治疗膀胱癌的临床效果。方法 选取2013年2月至2016年4月扬州市人民医院收治的80例膀胱癌患者作为研究对象,依据治疗方式的不同将患者分成两组,研究组采用经尿道电切术联合吉西他滨灌注治疗,对照组采用经尿道电切术联合吡柔比星灌注治疗,比较两组患者的治疗效果。结果 研究组患者各项观察指标均优于对照组(P <0.05)。结论 经尿道电切术联合吉西他滨灌注治疗膀胱癌的临床效果良好,可有效减少复发率和不良反应,帮助提高患者的生活质量。 Objective To analyze the clinical effect of transurethral resection combined with gemcitabine in the treatment of bladder cancer.Methods Eighty patients with bladder cancer admitted to our hospital from February 2013 to April 2016 were selected as subjects.Patients were divided into two groups according to different treatment methods.The study group was treated with transurethral resection combined with gemcitabine perfusion.The control group was treated with transurethral resection combined with pirarubicin infusion.Treatment effect was compared between the two groups.Results The observation indexes of the study group were better than the control group(P<0.05).Conclusion Transurethral resection combined with gemcitabine infusion for the treatment of bladder cancer has a good clinical effect,which can effectively reduce the recurrence rate and adverse reactions,and help improve the quality of life of patients.
作者 费尚春 FEI Shangchun(Department of Urology,Yangzhou People's Hospital,Yangzhou,Jiangsu 225001,China)
出处 《大医生》 2019年第3期75-76,共2页 Doctor
关键词 经尿道电切术 灌注治疗 吉西他滨 观察指标 膀胱癌患者 吡柔比星 不良反应 复发率 transurethral resection gemcitabine perfusion bladder cancer clinical effect
  • 相关文献

参考文献7

二级参考文献53

  • 1黄健.膀胱癌诊断治疗指南[M]//那彦群,叶章群,孙颖浩等.中国泌尿外科疾病诊断治疗指南(2014版),北京:人民卫生出版社,2014:36-37.
  • 2Witjes JA.The impact of recurrent non-muscle-invasive bladder cancer on progression[J].Eur Urol,2013,63(1):155-157.
  • 3Brandau S.Local and systemic immune suppression in bladder cancer[J].J Urol,2007,177(1):12-13.
  • 4Sylvester RJ,van der Meijden AP,Oosterlinck W,et al.Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC Risk Tables:A combined analysis of 2596 patients from seven EORTC trials[J].Eur Urol,2006,49(3):466-477.
  • 5Borkowska EM,Jedrzejczyk A,Marks P,et al.EORTC risk tables-their usefulness in the assessment of recurrence and progression risk in non muscle invasive bladder cancer in Polish patients[J].Cent European J Urol,2013,66(1):14-20.
  • 6Carballido J,Alvarezmon M,Soloverao J,et al.Clinical significance of natural killer activity in patients with transitional cell carcinoma of the bladder[J].J Urol,1990,143(1):29-33.
  • 7Bunimovich-Mendrazitsky S,Claude Gluckman J,Chaskalovic J.A mathematical model of combined BCG and IL-2 immunotherapy of superficial bladder cancer[J].J Theor Biol,2011,277(1):27-40.
  • 8Vang DP,Wurz GT,Griffey SM,et al.Induction of invasive transitional cell bladder carcinoma in immune intact human MUC1 transgenic mice:a model for immunotherapy development[J].J Vis Exp,2013,30(80):e50868.
  • 9Breban R,Bisiaux A,Biot C,et al.Mathematical model of tumor immunotherapy for bladder carcinoma identifies the limitations of the innate immuneresponse[J].Oncoimmunology,2012,1(1):9-17.
  • 10Otto W,Denzinger S,Wieland WF,et al.First analysis of immune cell infiltration in stage pT1 urothelial bladder carcinoma:CD3 positivity as a prognostic marker for cancer-specific survival[J].World J Urol,2012,30(6):875-877.

共引文献79

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部